SIRPA and cancer: Furthermore, the dual blockade of CD47/SIRPα and PD-1/PD-L1 signaling, which respectively suppress innate and adaptive immune responses, has shown enhanced therapeutic efficacy in various cancer types, providing a promising avenue for cancer treatment that stimulates both arms of the immune system [88].